Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669630 | 0.86 | GCK (0.54) | GCKKCNH2CYP2C9 | |
| SCHEMBL2657842 | 0.86 | GCK (0.61) | GCK | |
| SCHEMBL2666292 | 0.86 | GCK (0.83) | GCKKCNH2 | |
| SCHEMBL1147155 | 0.86 | GCK (0.83) | GCKKCNH2 | |
| SCHEMBL1132778 | 0.84 | GCK (1.00) | GCKKCNH2 | |
| SCHEMBL12824138 | 0.83 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL16473234 | 0.83 | GCK (0.79) | GCKKCNH2 | |
| SCHEMBL2666228 | 0.83 | GCK (0.78) | GCKKCNH2 | |
| SCHEMBL1146868 | 0.83 | GCK (0.78) | GCKKCNH2 | |
| SCHEMBL1133395 | 0.81 | GCK (1.00) | GCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197849-B1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | claimed |
| EP-2197849-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-23 | — | — | EP | claimed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | claimed |
| EP-2197849-B1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2197849-B1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2197849-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, HK1, GCK | GCK 3/4885KCNH2 240/4885CYP2C9 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.